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Background: The aim of this study was to evaluate the clinical usefulness of a semiquantitative 
procalcitonin kit for assessing severity of sepsis and early determination of mortality in affected 
patients.
Methods: This was a prospective, observational study including 206 septic patients enrolled 
between June 2008 and August 2009. Disseminated intravascular coagulation (DIC), Sequential 
Organ Failure Assessment (SOFA), Acute Physiology and Chronic Health Evaluation 
(APACHE) II scores were measured, along with semiquantitative procalcitonin concentrations. 
Patients were divided into three groups based on their semiquantitative procalcitonin concentra-
tions (group A, ,2 ng/mL; group B $ 2 ng/mL , 10 ng/mL; group C $ 10 ng/mL).
Results: A significant difference in DIC, SOFA, and APACHE II scores was found between 
group A and group C and between group B and group C (P , 0.01). Patients with severe sepsis 
and septic shock had significantly higher procalcitonin concentrations than did patients with 
less severe disease. The rate of patients with septic shock with high procalcitonin concentra-
tions showed an upward trend. There was a significant (P , 0.01) difference between the three 
groups with regard to numbers of patients and rates of severe sepsis, septic shock, DIC, and 
mortality.
Conclusion: Semiquantitative procalcitonin concentration testing can be helpful for early 
assessment of disease severity in patients with sepsis. Furthermore, it may also help in predicting 
early mortality in septic patients. Based on the level of semiquantitative procalcitonin measured 
in patients with suspected sepsis, a timely decision can be reliably made to transfer them to a 
tertiary hospital with an intensive care unit for optimal care.
Keywords: sepsis, semiquantitative procalcitonin, Sequential Organ Failure Assessment, Acute 
Physiology and Chronic Health Evaluation II, mortality, procalcitonin
Introduction
Sepsis is one of the most significant causes of mortality in the intensive care unit. Recent 
international guidelines for management of severe sepsis and septic shock1 recommend 
early diagnosis and treatment of sepsis because any delay may lead to a more serious 
outcome, ie, fatal organ failure and death.2 A diagnosis of sepsis is based on evidence 
of infection along with the presence of systemic inflammatory response syndrome, 
defined by the presence of two or more of the following: elevated or lowered body 
temperature, abnormal white blood cell count, elevated heart rate, and high respiratory 
rate.3 It has been documented that quantitative evaluation of procalcitonin is useful 
for discriminating between patients with bacterial infection and those with systemic 
inflammatory response syndrome caused by another illness.4–8 Similarly, many studies 
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have reported that quantitative procalcitonin values may help 
to discriminate between patients with severe sepsis infection 
and septic shock and those with less severe conditions.4–13 
Quantitative procalcitonin concentration is significantly 
correlated with both the Sequential Organ Failure Assess-
ment (SOFA)14 score and the Acute Physiology and Chronic 
Health Evaluation (APACHE) II15 score,13,16,17 and significant 
differences in quantitative procalcitonin concentrations have 
been found between patients with and without septic shock.13 
A quantitative procalcitonin concentration is also useful as an 
early prognostic indicator; among patients with septic shock, 
those who died in the intensive care unit had significantly 
higher quantitative procalcitonin concentrations at all assay 
time points than those who survived to be discharged from 
an intensive care unit.18
Due to the cost of procalcitonin analysis, hospitals with 
the capability to measure quantitative procalcitonin concen-
trations are limited to larger facilities with intensive care 
units. However, in hospitals and medical clinics without 
intensive care units, it is important to diagnose sepsis early 
and to make an estimate of severity in support of an early 
decision to transfer patients to a hospital with an intensive 
care unit so that they may receive optimal care. Therefore, 
semiquantitative procalcitonin measurement may benefit 
patients in hospitals and medical clinics without intensive 
care units.
A semiquantitative procalcitonin test kit is easy to use at 
the bedside. Research indicates that semiquantitative procal-
citonin concentration ranges are well correlated with those 
of quantitative procalcitonin measurements.19,20 However, 
to the best of our knowledge, no study has reported on the 
usefulness of a semiquantitative procalcitonin kit for esti-
mating severity and determining the prognosis of sepsis. 
Therefore, the aim of this study was to evaluate the clinical 
usefulness of a semiquantitative procalcitonin kit for assess-




This prospective observational study was conducted in 
the Department of General Medicine and Emergency 
Department of Toyooka Public Hospital, Hyogo, Japan, a 
500-bed teaching hospital that has been designated as the 
major emergency center of the North Hyogo province by the 
Japanese government. The local ethics committee approved 
the study and waived the requirement for written informed 
consent. Patients were evaluated for the presence of systemic 
inflammatory response syndrome and sepsis as defined by 
American College of Chest Physicians/Society of Critical 
Care Medicine guidelines.3 Systemic inflammatory response 
syndrome was defined as a systemic inflammatory response to 
an unspecified stimulus manifested by the presence of two or 
more of the following: body temperature , 36°C or .38°C, 
heart rate . 90 beats per minute, respiratory rate . 20 
breaths per minute or PaCO2 , 32 Torr (mmHg), and white 
blood cell count . 12,000 cells/mm3, ,4000 cells/mm3, 
or .10% band forms (immature white blood cells). Sepsis 
was diagnosed when patients met criteria for systemic inflam-
matory response syndrome and an infectious source was 
documented or strongly suspected on the basis of clinical 
appearance.3 We excluded patients younger than 18 years of 
age as well as patients with do not resuscitate status, those 
with liver cirrhosis, those receiving warfarin, and individuals 
with evidence of traumatic injury. The patients included 
were consecutively enrolled from June 2008 to August 2009. 
Semiquantitative procalcitonin concentrations and C-reactive 
protein were measured on admission. SOFA and APACHE II 
scores were determined on the day of   admission. Blood 
pressure, body temperature, pulse rate, respiratory rate, white 
blood cell count, Glasgow Coma Scale,21 serum albumin 
level, and antithrombin activity level were also measured. 
The maximum C-reactive protein value was defined as the 
highest level recorded during the first 48 hours of hospital 
admission.
The final diagnosis was determined by the physician 
based on clinical course in the hospital. Systemic inflam-
matory response syndrome, severe sepsis, and septic shock 
were diagnosed based on the criteria of the Consensus Con-
ference of the American Society of Chest Physicians/Society 
of Critical Care Medicine.3 A diagnosis of disseminated 
intravascular coagulation (DIC) was based on the diagnostic 
criteria established by the Japanese Association for Acute 
Medicine.22 All patients were followed up for 28 days after 
enrollment in the study, and 28-day all-cause mortality was 
assessed.
Procalcitonin measurement
Procalcitonin was measured using the semiquantitative Pro-
calcitonin-Q® test kit (Brahms Ag Diagnostica, Berlin, Ger-
many). Procalcitonin-Q is a rapid immunochromatographic 
test performed by pipetting 200 µL of serum onto a test strip, 
with results available in 30 minutes. The manufacturer’s 
reference scale categorizes four procalcitonin level intervals, 
ie, ,0.5 ng/mL, $0.5 ng/mL and ,2 ng/mL, $2 ng/mL and 
,10 ng/mL, and $10 ng/mL.
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Previous reports have shown that quantitative procalcitonin 
concentrations above 2 ng/mL discriminate between patients 
with systemic inflammatory response syndrome, severe bacte-
rial infections, and sepsis, and patients with systemic inflam-
matory response syndrome, sepsis, and organ failure.17,23 
It is also suspected that a semiquantitative procalcitonin 
concentration above 2 ng/mL indicates the presence of bac-
terially induced systemic inflammatory response syndrome.24 
Therefore, patients were divided into three groups based 
on semiquantitative procalcitonin concentrations: group A 
comprised patients showing semiquantitative procalcitonin 
results , 2 ng/mL; group B had semiquantitative procalci-
tonin results $ 2 ng/mL and ,10 ng/mL; and group C had 
semiquantitative procalcitonin results $ 10 ng/mL.
Statistical analysis
The statistical significance of differences were determined using 
the analysis of variance or the Chi-square test. Calculations 
were performed with R, version 2.12.1 (R Foundation for 
Statistical Computing, Vienna, Austria), and P values , 0.05 
were considered to be statistically significant.
Results
A total of 206 patients were enrolled in the study, were of 
mean age 75.8 ± 13.5 (range 23–103) years, and had a male-
to-female ratio of 113:93. Table 1 shows the infection sites 
in the 206 patients. The enrolled patients were divided into 
three groups as follows: group A, comprising 84 patients 
(46 with a procalcitonin concentration , 0.5 ng/mL and 
38 with procalcitonin $0.5 and ,2 ng/mL); group B, 
  including 39 patients; and group C with 83 patients. The 
clinical data for each group are shown in Table 2. Systolic 
blood pressure and mean blood pressure significantly 
decreased in groups B and C as compared with group A. 
Furthermore, group C patients showed increased respiratory 
rates compared with groups A and B. The antithrombin 
  activity level was significantly decreased in groups B and C 
as compared with group A. Table 3 shows mean DIC, SOFA, 
Table 1 Infection sites in patients
Infection site Patients (n)
respiratory system 
  Pneumonia 











  Liver abscesses 






Soft tissue system 
  Cellulitis 





  Colon diverticulitis 







  Iliopsoas muscle abscess 
  Purulent meningitis 
  Acute tonsillitis 
  Infective endocarditis 







Table 2 Clinical data for study patient groups according to procalcitonin level







A vs B A vs C B vs C
n 84 39 83
Gender (male/female) 42/42 26/13 38/47
Age (years) 75.3 ± 15.1 76.1 ± 13.4 76.4 ± 12.2 1.00 1.00 1.00
Systolic BP (mmHg) 125.6 ± 22.6 117.2 ± 23.0 102.1 ± 21.6 0.049 ,0.001 0.001
Diastolic BP (mmHg) 71.1 ± 14.6 63.1 ± 14.7 57.8 ± 15.0 0.03 ,0.001 0.049
Mean BP (mmHg) 88.8 ± 15.2 81.1 ± 16.5 72.6 ± 16.0 0.014 0.001 ,0.001
respiratory rate (per minute) 22.6 ± 4.7 23.8 ± 4.9 26.0 ± 5.9 0.32 ,0.001 0.05
Heart rate (beats per minute) 92.3 ± 22.7 101.2 ± 19.5 102.8 ± 21.8 0.11 ,0.001 0.82
Temperature (°C) 37.9 ± 1.7 38.5 ± 1.0 38.1 ± 2.1 0.34 0.51 0.51
GCS score 13.8 ± 2.4 13.4 ± 2.4 12.9 ± 3.1 0.41 0.08 0.62
WBC (×1000/µL) 13.1 ± 6.2 14.7 ± 7.5 13.5 ± 8.1 0.84 0.85 0.85
Maximum CrP (mg/dL) 15.0 ± 8.5 17.8 ± 7.8 19.5 ± 9.5 0.25 0.001 0.33
Albumin (g/dL) 2.87 ± 0.55 2.65 ± 0.54 2.49 ± 0.48 0.09 ,0.001 0.14
AT activity (%) 82.3 ± 14.9 74.3 ± 14.5 61.7 ± 16.3 0.01 ,0.001 ,0.001
Abbreviations: AT, antithrombin; BP, blood pressure; GCS, Glasgow Coma Scale; WBC, white blood cells; CrP, C-reactive protein; vs, versus.
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and APACHE II scores in each procalcitonin group. A sig-
nificant difference in DIC, SOFA, and APACHE II scores 
was found between group A and group C and between group 
B and group C. Figure 1 shows a comparison of semiquan-
titative procalcitonin concentration with the rate of severe 
sepsis and septic shock. In group C, the rates of patients 
with severe sepsis and septic shock were extremely high, at 
76% and 51%, respectively. Figure 2 shows a comparison of 
semiquantitative procalcitonin concentration with the rate 
of DIC and 28-day all-cause mortality. The mortality rate, 
at 13% in group C, is obviously high.
Table 4 shows the numbers of patients and rates of 
severe sepsis, septic shock, DIC, and mortality in each 
procalcitonin group. The results were significantly dif-
ferent between three groups. For numbers of patients and 
rates of severe sepsis, septic shock, DIC, and mortality, the 
value in group C was higher than expected and the value in 
group A was lower than expected from the adjusted residual 
error. All mortality was due to infection. No other cause 
of death was documented. Almost all patients with septic 
shock were in group C (procalcitonin $ 10). Approximately 
60% of patients with DIC were in group C, and there were 
few patients with DIC in group A. Moreover, the mortality 
rate was highest in group C, which also had the highest 
procalcitonin level.
Discussion
Our results show that semiquantitative procalcitonin concen-
tration is an important discriminator for severity of sepsis. 
Furthermore, it may help in predicting early mortality in 
patients with sepsis. The results for systolic blood pressure, 
mean blood pressure, and respiratory rates may reflect sever-
ity of circulatory failure and respiratory failure. Antithrombin 
activity levels have been reported to be of prognostic value 
for the prediction of death in patients with severe sepsis or 
septic shock.25,26 Our results suggest that the semiquantitative 
procalcitonin concentration is indirectly a predictor of death 
in these patients.
In the present study, SOFA and APACHE II scores were 
significantly increased in group C as compared with groups 
A and B. Higher SOFA and APACHE II scores have been 
associated with significantly higher quantitative procalci-
tonin concentrations in several previous studies.13,16,17 Our 
results show that semiquantitative procalcitonin concentra-
tion is an important discriminator that can evaluate sepsis 
severity as well as quantitative procalcitonin concentration. 
Table 3 DIC score, SOFA score, and APACHE II score for each group divided by procalcitonin level







A vs B A vs C B vs C
DIC score 1.52 ± 1.06 1.80 ± 1.24 2.99 ± 2.19 1.00 ,0.001 0.001
APACHE II score 12.7 ± 6.3 15.7 ± 5.8 20.5 ± 7.8 0.074 ,0.001 0.001
SOFA score   1.9 ± 1.8   3.1 ± 2.3   5.2 ± 3.1 0.057 ,0.001 ,0.001





A; PCT < 2 B; 2 ≤ PCT < 10
Semi-quantitative PCT concentrations









Figure 1 Comparison of semiquantitative procalcitonin concentrations with rates of severe sepsis and septic shock.
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In group C, rates of patients with severe sepsis and septic 
shock were extremely high. This result using semiquantita-
tive procalcitonin measurement is similar to that found with 
quantitative procalcitonin measurement, where significant 
differences are apparent in quantitative procalcitonin 
concentrations between patients with and without septic 
shock.13 The rate of patients with DIC also showed an 
upward trend with increasing semiquantitative procalci-
tonin   concentrations. These results strongly suggest that 
semiquantitative procalcitonin concentration is a predictor 
of severity in patients with sepsis. While septic shock is a 
clinical diagnosis, severe sepsis (sepsis with acute organ 
failure) is a complicated diagnosis that can utilize several 
different organ failure assessments. The procalcitonin assay 
correlates with the presence of severe sepsis and can be 
helpful in the early triage of this patient population.
The mortality rate, which was 13% in group C, is obvi-
ously high. Also, the value in group C was higher than 
expected. Semiquantitative procalcitonin concentration may 
be of great initial prognostic value. In hospitals and medical 
clinics without intensive care units, it is important to diagnose 
sepsis early and to make an estimate of severity in support 
of an early decision to transport patients to a hospital with 
an intensive care unit so they may receive optimal care. Our 
study may contribute to making a timely decision to transfer 
them to a tertiary hospital with an intensive care unit.
This study had several limitations. First, the timing of 
onset of infection was not considered, although it is known 
that serum procalcitonin begins to rise within 2–4 hours 
and shows peak levels at 6 hours.27 Therefore some patients 
may have been measured before procalcitonin began to 
rise. Second, because we used clinical and microbiological 
evidence, it might have been difficult to ascertain the precise 
cause of sepsis in all patients, and this might have intro-
duced some misclassification bias. Finally, the conduct of 
this study was confined to departments in single centers, so 
case numbers were limited, and multicenter validation would 
have increased the generalizability of such findings.
In conclusion, semiquantitative procalcitonin concentra-
tion testing can be helpful for early assessment of disease 
severity in patients with sepsis. Furthermore, it may help in 
predicting early mortality in patients with sepsis. Based on the 
level of semiquantitative procalcitonin measured in patients 
with suspected sepsis, a timely decision can be reliably made 
to transfer them to a tertiary hospital with an intensive care 
unit for optimal care.
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Figure 2 Comparison of semiquantitative procalcitonin concentrations with rate of disseminated intravascular coagulation and mortality.
Abbreviations: DIC, disseminated intravascular coagulation.
Table 4 numbers of patients and rates of severe sepsis, septic 
shock, disseminated intravascular coagulation, and mortality for 
each group according to procalcitonin level







Severe sepsis 15 (19%) 20 (51%) 63 (76%) ,0.0001
Septic shock 2 (2%) 5 (13%) 42 (51%) ,0.0001
DIC 3 (4%) 8 (21%) 31 (37%) ,0.0001
Mortality 1 (1%) 1 (3%) 11 (13%) 0.003
Abbreviations: DIC, disseminated intravascular coagulation; PCT, procalcitonin.
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